Effective Treatment Options for Keloid Scars: A Comprehensive Guide

# Effective Treatment Options for Keloid Scars: A Comprehensive Guide

The Challenge of Treating Keloid Scars

Keloid scars are challenging to treat due to their tendency to recur and their resistance to many conventional scar therapies. Unlike normal scars, keloids grow beyond the boundaries of the original wound, forming raised, often itchy and painful lesions. The primary goal of keloid treatment is to reduce symptoms, improve cosmetic appearance, and prevent recurrence. Given the complex nature of keloid formation, a single treatment modality is often insufficient, and a combination approach is frequently employed. The choice of treatment depends on several factors, including the size, location, and age of the keloid, as well as the patient's medical history and previous treatment responses [1].

Non-Surgical Treatment Modalities

Non-surgical treatments are often the first line of defense, especially for smaller or newer keloids, and are frequently used in conjunction with other therapies:

* Corticosteroid Injections: Intralesional injections of corticosteroids (e.g., triamcinolone acetonide) are a cornerstone of keloid treatment. They work by reducing inflammation, inhibiting collagen synthesis, and decreasing fibroblast activity, leading to flattening and softening of the keloid. Multiple injections are usually required over several weeks or months [2].

* Silicone Sheeting and Gels: These topical treatments are thought to work by increasing hydration of the stratum corneum, which may reduce collagen production. They are non-invasive and can be effective for both prevention and treatment, especially when used consistently for several months [3].

* Pressure Therapy: Applying continuous pressure to a healing wound or existing keloid can help prevent its growth and flatten it. This is often achieved with custom-made pressure garments or clips, particularly effective for earlobe keloids after piercing or surgery. Pressure therapy needs to be maintained for several months to a year for optimal results [4].

* Cryotherapy: This involves freezing the keloid with liquid nitrogen, which causes cell damage and reduces blood supply to the scar. Cryotherapy can flatten keloids and reduce symptoms, often used in combination with corticosteroid injections to enhance efficacy [5].

* Laser Therapy: Various lasers, such as pulsed dye lasers, can be used to reduce the redness and flatten keloids by targeting blood vessels and promoting collagen remodeling. Laser therapy is often used as an adjunctive treatment [6].

Surgical Excision and Adjuvant Therapies

Surgical removal of keloids is an option for larger or more resistant lesions, but it carries a high risk of recurrence if not combined with adjuvant therapies. The act of surgery itself creates a new wound, which can trigger another keloid formation. Therefore, surgical excision is almost always followed by one or more adjuvant treatments to minimize recurrence:

* Surgical Excision: The keloid is carefully cut out. This is typically followed immediately by other treatments.

* Post-Surgical Corticosteroid Injections: Injections are given into the wound site immediately after surgery and continued for several months to prevent recurrence.

* Radiation Therapy: Low-dose radiation therapy applied shortly after surgical excision has shown significant success in preventing keloid recurrence, particularly for large or recurrent keloids. It works by inhibiting fibroblast proliferation and collagen synthesis [7].

* Fluorouracil (5-FU) Injections: This chemotherapy drug can be injected into keloids, sometimes in combination with corticosteroids, to inhibit fibroblast growth and reduce scar size.

Emerging and Combination Therapies

Research continues to explore new and more effective treatments for keloids. Combination therapies are increasingly recognized as the most effective approach, tailoring treatments to the individual patient and keloid characteristics. Emerging therapies include novel biologics, gene therapy, and targeted molecular therapies aimed at the underlying mechanisms of keloid formation [8].

Medical Disclaimer

The information provided in this article is for educational purposes only and is not intended as medical advice. Always consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.

References

[1] Mayo Clinic. (2023, July 13). Keloid scar - Diagnosis and treatment. [https://www.mayoclinic.org/diseases-conditions/keloid-scar/diagnosis-treatment/drc-20520902](https://www.mayoclinic.org/diseases-conditions/keloid-scar/diagnosis-treatment/drc-20520902)

[2] American Academy of Dermatology (AAD). (n.d.). Keloid scars: Diagnosis and treatment. [https://www.aad.org/public/diseases/a-z/keloids-treatment](https://www.aad.org/public/diseases/a-z/keloids-treatment)

[3] Cleveland Clinic. (n.d.). Keloid Scar: What It Is, Symptoms, Treatment & Removal. [https://my.clevelandclinic.org/health/diseases/keloid-scar](https://my.clevelandclinic.org/health/diseases/keloid-scar)

[4] American Academy of Family Physicians (AAFP). (2009, August 1). Management of Keloids and Hypertrophic Scars. [https://www.aafp.org/pubs/afp/issues/2009/0801/p253.html](https://www.aafp.org/pubs/afp/issues/2009/0801/p253.html)

[5] The Derm Digest. (n.d.). The dermatologist's guide to treating keloids: 5 pearls and promising future therapies. [https://thedermdigest.com/the-dermatologists-guide-to-treating-keloids-5-pearls-and-promising-future-therapies/](https://thedermdigest.com/the-dermatologists-guide-to-treating-keloids-5-pearls-and-promising-future-therapies/)

[6] NYU Langone Health. (n.d.). Surgery for Scars & Keloids. [https://nyulangone.org/conditions/scars-keloids/treatments/surgery-for-scars-keloids](https://nyulangone.org/conditions/scars-keloids/treatments/surgery-for-scars-keloids)

[7] Look Natural. (n.d.). Keloid Removal Surgery & Treatments. [https://www.looknatural.com/surgical-procedures/body/keloid-removal](https://www.looknatural.com/surgical-procedures/body/keloid-removal)

[8] PMC. (2024). A Comprehensive Review of Non-Surgical Treatments for Hypertrophic Scars and Keloids. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11193462/](https://pmc.ncbi.nlm.nih.gov/articles/PMC11193462/)

Understanding Keloid Pathophysiology for Better Treatment Outcomes

Effective keloid treatment requires understanding why standard wound healing goes wrong. Keloid fibroblasts differ from normal fibroblasts in several key ways:

Abnormal TGF-β signaling:

Transforming growth factor beta-1 (TGF-β1) is the master regulator of fibrosis. In keloid tissue, TGF-β1 is overexpressed and its downstream signaling pathways (SMAD2/3) are constitutively activated. This drives continuous collagen production even in the absence of ongoing injury.

Resistance to apoptosis:

Normal fibroblasts undergo programmed cell death (apoptosis) as wounds mature, reducing scar bulk. Keloid fibroblasts overexpress anti-apoptotic proteins (Bcl-2, survivin) and are resistant to apoptotic signals. This is why keloids continue to grow.

Hypoxia and angiogenesis:

Keloid tissue is paradoxically hypoxic (low oxygen) despite being highly vascular. This hypoxic environment activates HIF-1α (hypoxia-inducible factor), which further stimulates TGF-β production and fibroblast proliferation.

Understanding these mechanisms explains why treatments targeting TGF-β signaling, fibroblast proliferation, and apoptosis resistance show the most promise.

Intralesional Corticosteroid Injections: First-Line Treatment

Intralesional corticosteroid injection (ICI) — typically triamcinolone acetonide (TAC) — is the most widely used first-line treatment for keloids.

Mechanism of action:

• Reduces collagen synthesis by suppressing fibroblast proliferation
• Induces apoptosis in keloid fibroblasts
• Reduces inflammatory mediators (IL-1, IL-6, TNF-α)
• Inhibits TGF-β1 signaling

Protocol:

• Concentration: 10–40 mg/mL of triamcinolone acetonide
• Injection interval: Every 4–6 weeks
• Number of sessions: Typically 3–6 sessions
• Technique: Intralesional injection (within the scar tissue, not subcutaneous)

Efficacy:

Response rates of 50–100% for symptom relief (itching, pain) and 50–80% for scar flattening have been reported. However, recurrence rates are high — 33–50% within 5 years.

Side effects:

• Skin atrophy (thinning) at injection site
• Hypopigmentation (lightening) — particularly concerning in darker skin tones
• Telangiectasias (small dilated blood vessels)
• Subcutaneous fat atrophy
• Systemic effects (rare): adrenal suppression with repeated high-dose injections

Combination approaches:

ICI combined with other treatments significantly improves outcomes:

• ICI + silicone sheeting: Reduces recurrence compared to ICI alone
• ICI + cryotherapy: Cryotherapy before injection softens the keloid, improving drug penetration
• ICI + surgical excision: Injections at time of suture removal and monthly thereafter reduce recurrence rates from 45–100% (surgery alone) to 10–50%

Cryotherapy: Freezing Keloids

Cryotherapy uses liquid nitrogen (−196°C) to freeze and destroy keloid tissue.

Mechanism:

Freezing causes intracellular ice crystal formation, cell membrane disruption, and vascular damage, leading to tissue necrosis. The resulting wound heals with less fibrotic tissue than the original keloid.

Techniques:

• Contact cryotherapy: Liquid nitrogen applied with a cotton swab or cryoprobe to the surface
• Intralesional cryotherapy: A hollow needle is inserted into the keloid and liquid nitrogen is circulated through it, freezing from the inside out. This technique is more effective for thick keloids.

Efficacy:

A 2020 systematic review found that intralesional cryotherapy achieved complete flattening in 51–74% of keloids, with recurrence rates of 0–24% at 1 year. It is particularly effective for earlobe keloids.

Side effects:

• Pain during and after treatment
• Hypopigmentation — a significant concern in patients with darker skin tones
• Blistering and crusting
• Hyperpigmentation (less common)

Laser Therapy for Keloids

Multiple laser modalities have been used for keloids, each with different mechanisms and evidence bases.

Pulsed dye laser (PDL, 585–595 nm):

PDL targets oxyhemoglobin in blood vessels, reducing vascularity and delivering heat to fibroblasts. It is most effective for red, vascular keloids and striae rubrae.

A 2014 meta-analysis found that PDL produced significant improvement in keloid vascularity, height, and symptoms, with response rates of 57–83%. It is generally well-tolerated with minimal risk of hypopigmentation.

Fractional CO2 laser:

Ablative fractional CO2 laser creates microscopic columns of thermal damage, stimulating collagen remodeling. It is more effective for mature, white keloids than PDL.

Nd:YAG laser (1064 nm):

Penetrates deeper than PDL and is better suited for darker skin tones where PDL carries higher hyperpigmentation risk.

Combination laser approaches:

Combining PDL with intralesional corticosteroids or 5-fluorouracil (5-FU) produces superior results to either treatment alone.

5-Fluorouracil (5-FU): An Emerging Treatment

5-FU is a chemotherapy agent that inhibits fibroblast proliferation by blocking DNA synthesis. It has shown significant promise for keloid treatment.

Intralesional 5-FU:

Injected directly into keloid tissue, typically at concentrations of 50 mg/mL, every 1–4 weeks.

Efficacy:

A 2009 randomized controlled trial comparing intralesional 5-FU to triamcinolone acetonide found similar efficacy but fewer side effects (particularly less hypopigmentation) with 5-FU. Combination 5-FU + TAC is now considered superior to either agent alone.

Side effects:

• Pain at injection site
• Ulceration (with high doses)
• Hyperpigmentation
• Systemic absorption is minimal with intralesional injection

Surgical Excision: When and How

Surgery alone for keloids has historically been associated with high recurrence rates (45–100%), as the surgical wound itself can trigger a new keloid. However, surgery combined with adjuvant therapy is effective.

Indications for surgery:

• Large keloids unresponsive to conservative treatment
• Keloids causing functional impairment (limiting joint movement, vision, hearing)
• Keloids causing severe psychological distress
• Keloids requiring tissue diagnosis to exclude malignancy

Surgical techniques:

• Intralesional excision: Leaving a rim of keloid tissue at the wound edges reduces the risk of recurrence compared to complete excision with normal tissue margins.
• Tension-free closure: Using Z-plasty or W-plasty techniques to redistribute wound tension reduces recurrence risk.
• Immediate adjuvant therapy: Corticosteroid injection at the time of surgery, followed by monthly injections for 6 months, reduces recurrence significantly.

Adjuvant radiation therapy:

Postoperative radiation therapy (typically 10–20 Gy in 3–5 fractions, delivered within 24–48 hours of surgery) reduces keloid recurrence rates to 10–30%. While concerns about radiation-induced malignancy exist, the absolute risk is very low for the doses used. Radiation is generally reserved for refractory keloids in adults.

Silicone Therapy: The Evidence Base

Silicone gel sheets and gels are the most evidence-based conservative treatment for keloids and hypertrophic scars.

Mechanism:

The exact mechanism is debated, but proposed effects include:

• Hydration of the stratum corneum, reducing keratinocyte stimulation of fibroblasts
• Reduction of TGF-β2 levels in scar tissue
• Reduction of collagen synthesis
• Static electricity effects that may influence fibroblast behavior

Clinical evidence:

A 2013 Cochrane review of 20 randomized controlled trials found moderate evidence that silicone gel sheeting reduces keloid recurrence after surgery and improves established keloid appearance. The evidence is stronger for prevention than treatment.

Protocol:

• Apply silicone sheets for 12–24 hours daily
• Duration: 3–6 months minimum
• Clean skin before application; allow to dry
• Wash sheets daily with mild soap

Emerging and Investigational Treatments

Botulinum toxin A (Botox):

Intralesional botulinum toxin A has shown promise in small studies. It reduces fibroblast proliferation and TGF-β1 production. A 2019 randomized trial found that botulinum toxin A combined with triamcinolone acetonide produced superior results to TAC alone.

Platelet-rich plasma (PRP):

PRP contains growth factors that may modulate fibroblast behavior. Paradoxically, some studies suggest PRP reduces keloid fibroblast activity despite containing TGF-β. Results are mixed and more research is needed.

Imiquimod:

This topical immune response modifier stimulates interferon-α production, which inhibits fibroblast proliferation. Used as adjuvant therapy after surgical excision, applied 3–5 nights per week for 8 weeks.

Verapamil:

A calcium channel blocker that inhibits fibroblast proliferation and collagen synthesis. Intralesional verapamil (2.5 mg/mL) has shown efficacy in small studies, particularly as an alternative to corticosteroids in patients who cannot tolerate steroid side effects.

Anti-TGF-β therapies:

Given TGF-β's central role in keloid pathogenesis, several TGF-β inhibitors are under investigation. Intralesional injection of anti-TGF-β1 antibodies has shown promise in early clinical trials.

Frequently Asked Questions

Q: How many treatment sessions will I need?

A: This varies by treatment and keloid characteristics. Intralesional corticosteroids typically require 3–6 sessions at 4–6 week intervals. Laser therapy typically requires 3–6 sessions. Cryotherapy may require 2–4 sessions. Combination approaches often require fewer total sessions.

Q: Will my keloid come back after treatment?

A: Keloid recurrence is common. Recurrence rates vary by treatment: surgery alone (45–100%), surgery + radiation (10–30%), intralesional corticosteroids alone (33–50%), cryotherapy (0–24%). Combination approaches and ongoing maintenance therapy reduce recurrence risk.

Q: Is there a cure for keloids?

A: There is currently no cure. All available treatments reduce keloid size and symptoms and reduce recurrence risk, but none guarantees permanent resolution. Research into TGF-β inhibitors and gene therapy may eventually offer more definitive treatments.

Q: How do I choose between treatment options?

A: The best treatment depends on keloid location, size, age, your skin type, and your medical history. Consult a board-certified dermatologist or plastic surgeon with keloid expertise. Most experts recommend starting with conservative approaches (silicone sheeting, intralesional corticosteroids) before proceeding to more invasive options.